Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
3/23/2023
Roche, CR Pharma Tie Up to Improve Access of Flu Drug Xofluza in Chna
3/23/2023
Chinese Government Issues the Opinions for Further Improving Healthcar...
3/23/2023
CDE Solicits Comments on the Dossier Requirements for Marketing Regist...
3/22/2023
Biohaven Licenses ex-China Rights of Highlightll Pharma's TYK2/JAK1 Du...
3/22/2023
NMPA Issues Announcement for Applicability of ICH Guidelines S1B(R1)/Q...
3/22/2023
CDE Solicits Comments on the Technical Guidelines for Virus Removal/In...
3/22/2023
TaiGen Enters Exclusive License Agreement with Joincare for Pan-influe...
3/21/2023
Chinese NCE Drug Approval in 2022: Import vs. Domestic
3/21/2023
Review of Chinese Drug Registration Application and Evaluation in 2022
3/21/2023
Bayer, Orion's Nubeqa Gets Approval in China for Expanded Use in Prost...
3/21/2023
CDE Issues the Technical Guidelines for Clinical Research and Developm...
3/21/2023
CDE Issues the Technical Guidelines for Writing of Pharmacy Informatio...
3/21/2023
CDE Issues the Technical Guidelines for Continuous Manufacturing of Ch...
3/21/2023
Therapeutic Antibody Licensing Deals in China: A 2022 End-Of-Year Summ...
3/20/2023
New Report: China Cell Therapy Market Opportunity & Clinical Trials In...
3/20/2023
TOT Biopharm Terminates Development of Its HER2 ADC TAA013 in China Du...
3/17/2023
BeiGene Drops Licensing Option for Leap Thera's I/O Candidate DKN-01
3/17/2023
J&J and Legend Shelve Carvykti's UK Launch amid Manufacturing Shortfa...
3/17/2023
CDE Solicits Comments on Draft Implementation Suggestions and Chinese ...
3/17/2023
CDE Issues the Technical Guidelines for Clinical Trial of Compound Che...
3/17/2023
CDE Issues the Guidelines for Safety Information Summary, Analysis and...
3/17/2023
CDE Issues the FAQs for Rapid Reporting of Safety Data During Drug Cli...
3/17/2023
CDE Issues the Technical Guidelines for Abuse Prevention Pharmaceutica...
3/17/2023
Recent Executive Moves
3/17/2023
Jinyao Pharma Fined CNY 28M for Abuse of Market Dominance to Sell Chem...
3/17/2023
Drug R&D and Product Registration News Digest March 2023 (3)
3/17/2023
Upgrading Medtech Commercial Operations in China (McKinsey)
3/16/2023
China Biotech Fundraising Up Sharply in February as Six Drugmakers Iss...
3/16/2023
ArkBio and Calibr Collaborate on Potential First-in-class Drug for Res...
3/16/2023
Ahead of Pfizer Takeover, Seagen Quietly Sign Deal for Certain Cell Th...
Page:
109
/
775
Total number of articles:
23244
:
[First]
[<<]
[107]
[108]
[109]
[110]
[111]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit